From GlobeNewswire: 2025-03-06 09:15:00

The Digital Neuro Biomarkers Market was valued at USD 538.96 million in 2023, expected to reach USD 4592.14 million by 2032 with a CAGR of 25.96%. Rising neurological disorders drive market growth, with wearable technology and AI integration enhancing diagnostics. Major players include Altoida Inc., Koneksa, Biogen Inc., and Roche. North America leads with a 35% market share, while the Asia-Pacific region shows the fastest growth potential. The prevalence of neurological diseases in countries like China, India, and Japan is driving growth in the digital therapeutics for CNS & neurological diseases market. Initiatives like India’s NPDI are enhancing accessibility to digital solutions, while Apple Watch and IBM Watson Health are introducing innovative ways to monitor and analyze neurological health in real-time.

In 2023, Apple Inc. launched a new feature in its Apple Watch to detect early signs of Parkinson’s disease. In January 2024, the FDA approved IBM Watson Health’s AI-powered digital biomarker platform for continuous analysis of wearable device data. These advancements are revolutionizing the way neurological health is monitored and managed.

The digital neuro biomarkers market analysis & outlook report for 2024-2032 covers key points such as market dynamics impact analysis, statistical insights, trends, research methodology, and regional analysis. The report also includes information on device volume, healthcare spending, research and development trends, adoption rates, competitive landscape, company profiles, and more. Access the complete report details for a comprehensive understanding of the market.



Read more at GlobeNewswire: Digital Neuro Biomarkers Market to Hit USD 4592.14 Million